World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya & Malawi that has reached more than 800 000 children since 2019.
The vaccine is developed by British drugmaker GlaxoSmithKline (GSK). Many vaccines exist against viruses and bacteria but this was the first time that the WHO recommended broad use of a vaccine against a human parasite. The vaccine acts against Plasmodium falciparum, one of five parasite species and the most deadly. The symptoms of malaria are fever, headaches, and muscle pain, then cycles of chills, fever, and sweating.
Important takeaways for all competitive exams:
The National Statistics Office (NSO) has announced a nationwide Survey on Migration, scheduled from July…
Kashmir is often described as one of the most beautiful regions in the world, known…
India and the European Union have taken a decisive step towards paperless global trade. On…
Andhra Pradesh has introduced an innovative digital tool for small businesses. On 2 February 2026,…
Indian-origin scientist Veerabhadran Ramanathan received the Crafoord Prize, widely known as the “Nobel of Geosciences.”…
The Responsible Nations Index 2026 has been released by the World Intellectual Foundation (WIF), marking…